<DOC>
	<DOCNO>NCT00062296</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy epirubicin use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining epirubicin rituximab may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine epirubicin rituximab treat patient relapsed refractory B-cell non-Hodgkin 's lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Epirubicin Rituximab Treating Patients With Relapsed Refractory B-Cell Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , time progression , overall survival patient refractory relapsed B-cell non-Hodgkin 's lymphoma chronic lymphocytic leukemia treat epirubicin rituximab . - Determine toxicity regimen patient . - Determine pharmacokinetics regimen patient . OUTLINE : This non-randomized , open-label , multicenter study . Patients receive epirubicin IV 3-5 minute weekly 6 week . Patients also receive rituximab IV week 2 5 course 1 week 1 4 remain course . Treatment repeat every 8 week maximum 3 course absence disease progression unacceptable toxicity . Patients follow every 3 month disease progression . PROJECTED ACCRUAL : A total 18-38 patient accrue study within 2.5-3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Bcell nonHodgkin 's lymphoma ( grade ) chronic lymphocytic leukemia meeting 1 follow criterion : Primary refractory disease Disease progression least 1 4 prior cytotoxic chemotherapy regimens Rituximab administer alone consider 1 prior regimen Highdose chemotherapy stem cell support consider 1 prior regimen Bidimensionally measurable evaluable disease outside prior irradiation port No clinical evidence CNS involvement PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Neutrophil count least 2,000/mm^3* Platelet count least 100,000/mm^3* NOTE : *Unless due bone marrow involvement Hepatic Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time upper limit normal ( ULN ) Renal Creatinine great 2 time ULN Cardiovascular No unstable angina No uncontrolled congestive heart failure LVEF least 45 % Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study treatment HIV negative No concurrent primary malignancy except basal cell squamous cell skin cancer , carcinoma situ , localize solid tumor cure 5 year ago No acute infection require systemic therapy No confusion , disorientation , major psychiatric illness would preclude understand informed consent PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 4 week since prior biologic therapy Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) Prior cumulative doxorubicin dose great 6 course 50 mg/m^2 Endocrine therapy Not specify Radiotherapy See Disease Characteristics No prior radiotherapy entire pelvis At least 4 week since prior radiotherapy Surgery Not specify Other More 7 day since prior cimetidine No concurrent cimetidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>